dc.contributor.author
Ottanà, Rosaria
dc.contributor.author
Paoli, Paolo
dc.contributor.author
Cappiello, Mario
dc.contributor.author
Nguyen, Trung Ngoc
dc.contributor.author
Adornato, Ilenia
dc.contributor.author
Del Corso, Antonella
dc.contributor.author
Genovese, Massimo
dc.contributor.author
Nesi, Ilaria
dc.contributor.author
Moschini, Roberta
dc.contributor.author
Naß, Alexandra
dc.contributor.author
Wolber, Gerhard
dc.contributor.author
Maccari, Rosanna
dc.date.accessioned
2021-04-19T13:04:54Z
dc.date.available
2021-04-19T13:04:54Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/30419
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-30160
dc.description.abstract
Diabetes mellitus (DM) is a complex disease which currently affects more than 460 million people and is one of the leading cause of death worldwide. Its development implies numerous metabolic dysfunctions and the onset of hyperglycaemia-induced chronic complications. Multiple ligands can be rationally designed for the treatment of multifactorial diseases, such as DM, with the precise aim of simultaneously controlling multiple pathogenic mechanisms related to the disease and providing a more effective and safer therapeutic treatment compared to combinations of selective drugs. Starting from our previous findings that highlighted the possibility to target both aldose reductase (AR) and protein tyrosine phosphatase 1B (PTP1B), two enzymes strictly implicated in the development of DM and its complications, we synthesised 3-(5-arylidene-4-oxothiazolidin-3-yl)propanoic acids and analogous 2-butenoic acid derivatives, with the aim of balancing the effectiveness of dual AR/PTP1B inhibitors which we had identified as designed multiple ligands (DMLs). Out of the tested compounds, 4f exhibited well-balanced AR/PTP1B inhibitory effects at low micromolar concentrations, along with interesting insulin-sensitizing activity in murine C2C12 cell cultures. The SARs here highlighted along with their rationalization by in silico docking experiments into both target enzymes provide further insights into this class of inhibitors for their development as potential DML antidiabetic candidates.
en
dc.format.extent
32 Seiten
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
multi-target ligands
en
dc.subject
diabetes mellitus
en
dc.subject
aldose reductase
en
dc.subject
protein tyrosine phosphatase 1B
en
dc.subject
4-thiazolidinones
en
dc.subject
molecular docking
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::616 Krankheiten
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::615 Pharmakologie, Therapeutik
dc.title
In Search for Multi-Target Ligands as Potential Agents for Diabetes Mellitus and Its Complications - A Structure-Activity Relationship Study on Inhibitors of Aldose Reductase and Protein Tyrosine Phosphatase 1B
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
330
dcterms.bibliographicCitation.doi
10.3390/molecules26020330
dcterms.bibliographicCitation.journaltitle
Molecules
dcterms.bibliographicCitation.journaltitle
MDPI
dcterms.bibliographicCitation.number
2
dcterms.bibliographicCitation.volume
26
dcterms.bibliographicCitation.url
https://doi.org/10.3390/molecules26020330
refubium.affiliation
Biologie, Chemie, Pharmazie
refubium.affiliation.other
Institut für Pharmazie
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.isPartOf.eissn
1420-3049